-
公开(公告)号：US12036389B2
公开(公告)日：2024-07-16
申请号：US17142425
申请日：2021-01-06
Applicant: Insulet Corporation
Inventor： Joon Bok Lee , Yibin Zheng , Jason O'Connor
CPC classification number: A61M5/1723 , A61M5/14244 , A61M2205/52 , A61M2230/201
Abstract: Exemplary embodiments provide an approach to predicting meal and/or exercise events for an insulin delivery system that otherwise does not otherwise identify such events. The insulin delivery system may use a model of glucose insulin interactions that projects estimated future glucose values based on a history of glucose values and insulin deliveries for a user. The predictions of meal events and/or exercise events may be based on residuals between actual glucose values and predicted glucose values. The exemplary embodiments may calculate a rate of change of the residuals over a period of time and compare the rate of change to thresholds to determine whether there likely has been a meal event or an exercise event. The insulin delivery system may then take measures to account for the meal event or the exercise event by the user.
-
公开(公告)号：US11439754B1
公开(公告)日：2022-09-13
申请号：US17539270
申请日：2021-12-01
Applicant: Insulet Corporation
Inventor： Joon Bok Lee , Yibin Zheng , Jason O'Connor , Ashutosh Zade
Abstract: Disclosed herein is a method for execution by a drug delivery device for determining an optimal dose of a liquid drug for current cycle of a medication delivery algorithm, the method utilizing a stepwise evaluation of a model and a cost function across a coarse search space consisting of coarse discrete quantities of the drug and a refined search space consisting of refined discrete quantities of the drug.
-
公开(公告)号：US12300375B2
公开(公告)日：2025-05-13
申请号：US18151582
申请日：2023-01-09
Applicant: INSULET CORPORATION
Inventor： David Nazzaro , Steven Cardinali , Nicholas Conte , Daniel Allis , Jason O'Connor , Joon Bok Lee , Ashutosh Zade , Timothy Henning , Thomas Metzmaker , Ian McLaughlin
Abstract: Disclosed are examples of a device, a system, methods and computer-readable medium products operable to implement functionality to determine and respond to a purpose of a meal. An algorithm or application may receive data that may include data related to a meal purpose from data sources and determine whether any of the data received from the plurality of data sources was received from a direct data source or an indirect data source. The data may be evaluated to determine a purpose of the meal. Based on the results of the evaluation, instructions may be generated to provide an appropriate response based on the determined purpose of the meal. The generated instructions to provide the appropriate response based on the determined purpose of the meal may be output.
-
公开(公告)号：US12090301B2
公开(公告)日：2024-09-17
申请号：US16404456
申请日：2019-05-06
Applicant: Insulet Corporation
Inventor： Jason O'Connor , Joon Bok Lee , Trang Ly , Yibin Zheng , Thomas Arnold Peyser , Jennifer Lena Schneider
CPC classification number: A61M5/1723 , A61B5/14532 , A61M5/14244 , A61M5/145 , A61B5/486 , A61B5/6832 , A61M2005/14208 , A61M2005/14252 , A61M2205/18 , A61M2205/52 , A61M2230/201
Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.
-
5.发明授权公开(公告)号：US11986630B2
公开(公告)日：2024-05-21
申请号：US16788892
申请日：2020-02-12
Applicant: Insulet Corporation
Inventor： Joon Bok Lee , Ashutosh Zade , Jason O'Connor , Trang Ly , Yibin Zheng , Connor Gullifer , Kyle Grover
CPC classification number: A61M5/1723 , G16H20/17 , A61M2202/07 , A61M2205/18 , A61M2205/3569 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2205/581 , A61M2205/583 , A61M2230/201
Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.
-
Patent Agency Ranking
公开(公告)号：US11833329B2
公开(公告)日：2023-12-05
申请号：US17123369
申请日：2020-12-16
Applicant: INSULET CORPORATION
Inventor： Joon Bok Lee , Jason O'Connor , Yibin Zheng
CPC classification number: A61M5/1723 , A61M5/14244 , A61M2005/14208 , A61M2205/3303 , A61M2205/3569 , A61M2205/502 , A61M2205/52 , A61M2230/201
Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide techniques to implement functionality to receive blood glucose measurements over a period of time. An average of missing blood glucose measurement values may be maintained over a predetermined time period. A count of a number of missing blood glucose measurement values over a period of time may be established. A controller may calculate a divergence of the number of missing blood glucose measurement values over the period of time from the average of missing blood glucose measurements over the predetermined time period. Based on a value of the divergence, a determination that a safety constraint for delivery of insulin is to be reduced. The safety constraint may be reduced by a predetermined percentage. An instruction to deliver an insulin dosage may be generated according to the reduced safety constraint may be forwarded to a wearable drug delivery device.
-
公开(公告)号：US11565039B2
公开(公告)日：2023-01-31
申请号：US16599729
申请日：2019-10-11
Applicant: INSULET CORPORATION
Inventor： Jason O'Connor , Joon Bok Lee , Ian McLaughlin , John D'Arco
Abstract: A drug delivery device may include an Inertial Measurement Unit (IMU) is provided. The IMU may include an accelerometer, a magnetometer, or a gyroscope. Motion parameters may be detected when the drug delivery device is shipped, being prepared for activation for use, or during use. The IMU may provide data indicative of a rapid deceleration, such as when a package containing the drug delivery device is dropped, or some other physical event experienced by the drug delivery device. The drug delivery device may also include internal or external pressure sensors or a blood glucose sensor that may coordinate with the IMU to provide additional feedback regarding the status of the device or user. A controller of the drug delivery device may generate a response depending on the particular parameters being monitored or may change device operational parameters as a result of detected system events.
-
公开(公告)号：US12121701B2
公开(公告)日：2024-10-22
申请号：US17582349
申请日：2022-01-24
Applicant: Insulet Corporation
Inventor： Joon Bok Lee , Jason O'Connor , Yibin Zheng , Ashutosh Zade
IPC: G16H20/17 , A61B5/00 , A61B5/145 , A61K38/22 , A61K38/26 , A61K38/28 , A61M5/14 , A61M5/142 , A61M5/172 , G16H40/67
CPC classification number: A61M5/1723 , A61B5/14532 , A61B5/4839 , A61B5/4866 , A61B5/7282 , A61K38/22 , A61K38/26 , A61K38/28 , A61M5/1408 , A61M5/14248 , G16H20/17 , G16H40/67 , A61M2205/502 , A61M2205/52 , A61M2205/8206 , A61M2230/201
Abstract: Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.
-
公开(公告)号：US11935637B2
公开(公告)日：2024-03-19
申请号：US16586499
申请日：2019-09-27
Applicant: INSULET CORPORATION
Inventor： Joon Bok Lee , Yibin Zheng , Jason O'Connor , Trang Ly , Eric Benjamin
CPC classification number: G16H20/17 , A61M5/1723 , G16H40/67 , A61M2205/18 , A61M2205/3584 , A61M2205/505 , A61M2230/201
Abstract: Disclosed are a device, a computer-readable medium, and techniques that provide an onboarding process and an adaptivity process for a drug delivery device. A processor executing an onboarding process determines whether a history of delivered insulin to a user meets certain sufficiency requirements. The onboarding process enables a processor to cause the drug delivery device to administer doses of insulin to a user according to an initial total daily insulin dose calculation that is determined based on the sufficiency of the insulin delivery history. The initial total daily insulin may be adapted according to the adaptivity process as new insulin delivery is collected. The insulin delivery history, when sufficient, may be used to set total daily insulin dosages that enable automated insulin delivery upon replacement of a drug delivery device. The adaptivity process may be implemented to modify an initial insulin delivery doses to provide adapted insulin delivery doses.
-
公开(公告)号：US11607493B2
公开(公告)日：2023-03-21
申请号：US16840483
申请日：2020-04-06
Applicant: INSULET CORPORATION
Inventor： Joon Bok Lee , Mengdi Li , Jason O'Connor , Yibin Zheng
IPC: G08B1/08 , A61M5/172 , G16H20/17 , G16H40/67 , G16H50/50 , G16H10/40 , G16H10/60 , G16H50/30 , G16H50/70 , G16H50/20 , H04L67/141
Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.023 seconds)
